The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
July 16, 2018
View Complete Issue         Table of Contents 2019 
Axicabtagene Ciloleucel (Yescarta) for B-Cell Lymphoma (online only)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Axicabtagene Ciloleucel (Yescarta) for B-Cell Lymphoma (online only)
July 16, 2018 (Issue: 1551)
The FDA has approved axicabtagene ciloleucel (Yescarta – Kite) for treatment of adults with relapsed or refractory CD19+ large B-cell lymphoma after ≥2 lines of systemic therapy. Yescarta is an individualized cellular product prepared from...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Axicabtagene Ciloleucel (Yescarta) for B-Cell Lymphoma (online only)
Article code: 1551f
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.